Inclusion Criteria

          1. Have a diagnosis of relapsed or refractory AML or ALL for Phase I and for Phase 2 have
             a diagnosis of relapsed or refractory AML with MLLr or NPM1

          2. Be > /= 18 years of age or 20 years if required by local regulation

          3. ECOG < /= 2

          4. WBC below 30,000/μL (hydroxyurea allowed)

          5. Glomerular filtration rate (GFR) ≥ 50 ml/min, assessed by the Cockcroft-Gault formula

          6. Total bilirubin ≤1.5 the upper limit of normal (ULN) (or ≤2.0 ULN for patients with
             known Gilbert's syndrome)

          7. Aspartate aminotransferase (AST) ≤3.0 times ULN

          8. Alanine aminotransferase (ALT) ≤3.0 times ULN

        Exclusion Criteria:

          1. Has a left ventricular ejection fraction (LVEF) <45%, as determined by ECHO

          2. Histological diagnosis of acute promyelocytic leukemia

          3. Received systemic calcineurin inhibitors within 4 weeks prior to the first dose of DSP
             5336

          4. Has had abnormal ECGs that are clinically significant, such as QT prolongation (QTc
             >450 msec for males and >470 msec for females, with QTc corrected according to
             Fridericia's formula [QTcF])

          5. Has an active, uncontrolled, bacterial, viral, or fungal infection requiring systemic
             therapy

          6. Receives concurrent sensitive substrates with a narrow safety window or strong
             inhibitors or inducers of CYP3A4/5, including specifically: ketoconazole, itraconazole
             and isavuconazole. Other antifungals that are used as standard of care to prevent or
             treat infections are permitted